BR112021022909A2 - Processo aprimorado de preparação de nanopartículas lipídicas carregadas com mrna - Google Patents
Processo aprimorado de preparação de nanopartículas lipídicas carregadas com mrnaInfo
- Publication number
- BR112021022909A2 BR112021022909A2 BR112021022909A BR112021022909A BR112021022909A2 BR 112021022909 A2 BR112021022909 A2 BR 112021022909A2 BR 112021022909 A BR112021022909 A BR 112021022909A BR 112021022909 A BR112021022909 A BR 112021022909A BR 112021022909 A2 BR112021022909 A2 BR 112021022909A2
- Authority
- BR
- Brazil
- Prior art keywords
- lipid nanoparticles
- improved process
- mrna
- loaded lipid
- preparing mrna
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title abstract 5
- 108020004999 messenger RNA Proteins 0.000 title abstract 5
- 239000002105 nanoparticle Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 238000005538 encapsulation Methods 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Botany (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962847837P | 2019-05-14 | 2019-05-14 | |
| PCT/US2020/032943 WO2020232276A1 (en) | 2019-05-14 | 2020-05-14 | Improved process of preparing mrna-loaded lipid nanoparticles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021022909A2 true BR112021022909A2 (pt) | 2022-01-25 |
Family
ID=70919274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021022909A BR112021022909A2 (pt) | 2019-05-14 | 2020-05-14 | Processo aprimorado de preparação de nanopartículas lipídicas carregadas com mrna |
Country Status (12)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| DK3864163T3 (da) | 2018-10-09 | 2024-05-06 | Univ British Columbia | Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed |
| CN113939282A (zh) | 2019-01-31 | 2022-01-14 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| US12678406B2 (en) | 2020-10-12 | 2026-07-14 | Translate Bio Inc. | Process of preparing ice-based lipid nanoparticles |
| CA3198411A1 (en) * | 2020-10-12 | 2022-04-21 | Translate Bio, Inc. | Improved process of preparing mrna-loaded lipid nanoparticles |
| MX2023004371A (es) * | 2020-10-14 | 2023-07-26 | George Mason Res Foundation Inc | Lípidos ionizables, y métodos de fabricación y uso de los mismos. |
| EP4763287A2 (en) | 2021-09-03 | 2026-06-24 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| CN115745815B (zh) * | 2021-09-03 | 2025-06-10 | 广州谷森制药有限公司 | 阳离子脂质化合物 |
| EP4422698A1 (en) | 2021-10-29 | 2024-09-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| KR102772764B1 (ko) * | 2021-11-10 | 2025-02-27 | 주식회사 에스엠엘바이오팜 | 트레할로즈 유도체 및 신규 구조 유지 화합물을 포함하는 핵산 의약품 전달용 지질나노입자의 약학 조성물 |
| WO2023092151A1 (en) * | 2021-11-22 | 2023-05-25 | Ohio State Innovation Foundation | Compositions and methods for the treatment of neurodegenerative disorders |
| EP4469091A1 (en) | 2022-01-28 | 2024-12-04 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| CA3248209A1 (en) | 2022-05-25 | 2023-11-30 | CureVac SE | Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH) |
| JP2023181989A (ja) * | 2022-06-13 | 2023-12-25 | 上海臻上医薬科技有限公司 | マイクロニードル注射製剤およびその使用 |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| KR20250153298A (ko) | 2023-03-08 | 2025-10-24 | 큐어백 에스이 | 핵산 전달을 위한 신규의 지질 나노입자 제형 |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| WO2026033123A1 (en) | 2024-08-08 | 2026-02-12 | Sanofi Pasteur Inc. | Lipid nanoparticle formulations for mrna delivery |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| CA2569664C (en) | 2004-06-07 | 2013-07-16 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| AU2009303345B2 (en) | 2008-10-09 | 2015-08-20 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| WO2010053572A2 (en) | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| SI2506857T1 (en) | 2009-12-01 | 2018-08-31 | Translate Bio, Inc. | Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases |
| EP4074693A1 (en) | 2011-06-08 | 2022-10-19 | Translate Bio, Inc. | Cleavable lipids |
| KR20220025112A (ko) | 2011-06-08 | 2022-03-03 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
| US9512073B2 (en) | 2011-10-27 | 2016-12-06 | Massachusetts Institute Of Technology | Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof |
| ES2967701T3 (es) * | 2013-03-15 | 2024-05-03 | Translate Bio Inc | Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas |
| WO2015184256A2 (en) | 2014-05-30 | 2015-12-03 | Shire Human Genetic Therapies, Inc. | Biodegradable lipids for delivery of nucleic acids |
| WO2016004318A1 (en) * | 2014-07-02 | 2016-01-07 | Shire Human Genetic Therapies, Inc. | Encapsulation of messenger rna |
| WO2016118724A1 (en) | 2015-01-21 | 2016-07-28 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| EP3247398A4 (en) | 2015-01-23 | 2018-09-26 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| RS63051B1 (sr) | 2015-12-22 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularnu isporuku agenasa |
| EP3442590A2 (en) | 2016-04-13 | 2019-02-20 | Modernatx, Inc. | Lipid compositions and their uses for intratumoral polynucleotide delivery |
| AU2017283479B2 (en) | 2016-06-13 | 2023-08-17 | Translate Bio, Inc. | Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency |
| US20180153822A1 (en) * | 2016-11-10 | 2018-06-07 | Translate Bio, Inc. | Process of Preparing mRNA-Loaded Lipid Nanoparticles |
| CA3077391A1 (en) * | 2017-09-29 | 2019-04-04 | Intellia Therapeutics, Inc. | In vitro method of mrna delivery using lipid nanoparticles |
| CN118436618A (zh) * | 2018-05-30 | 2024-08-06 | 川斯勒佰尔公司 | 信使rna疫苗及其用途 |
| US20220016265A1 (en) * | 2018-11-09 | 2022-01-20 | Translate Bio, Inc. | Messenger rna therapy for treatment of ocular diseases |
-
2020
- 2020-05-14 AU AU2020274758A patent/AU2020274758B2/en active Active
- 2020-05-14 CN CN202080049849.1A patent/CN114126588A/zh active Pending
- 2020-05-14 EP EP20729587.4A patent/EP3968952A1/en active Pending
- 2020-05-14 MX MX2021013959A patent/MX2021013959A/es unknown
- 2020-05-14 SG SG11202112574RA patent/SG11202112574RA/en unknown
- 2020-05-14 WO PCT/US2020/032943 patent/WO2020232276A1/en not_active Ceased
- 2020-05-14 US US17/611,020 patent/US20220218612A1/en active Pending
- 2020-05-14 CA CA3140423A patent/CA3140423A1/en active Pending
- 2020-05-14 KR KR1020217040794A patent/KR20220024022A/ko not_active Ceased
- 2020-05-14 JP JP2021568011A patent/JP7707080B2/ja active Active
- 2020-05-14 BR BR112021022909A patent/BR112021022909A2/pt unknown
-
2021
- 2021-11-11 IL IL288020A patent/IL288020A/en unknown
-
2025
- 2025-03-05 JP JP2025034187A patent/JP2025084968A/ja active Pending
- 2025-07-28 AU AU2025208550A patent/AU2025208550A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220218612A1 (en) | 2022-07-14 |
| JP7707080B2 (ja) | 2025-07-14 |
| SG11202112574RA (en) | 2021-12-30 |
| CN114126588A (zh) | 2022-03-01 |
| AU2020274758A1 (en) | 2021-12-23 |
| WO2020232276A1 (en) | 2020-11-19 |
| KR20220024022A (ko) | 2022-03-03 |
| AU2020274758B2 (en) | 2025-05-01 |
| MX2021013959A (es) | 2022-04-01 |
| IL288020A (en) | 2022-01-01 |
| JP2022532213A (ja) | 2022-07-13 |
| CA3140423A1 (en) | 2020-11-19 |
| EP3968952A1 (en) | 2022-03-23 |
| JP2025084968A (ja) | 2025-06-03 |
| AU2025208550A1 (en) | 2025-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021013959A (es) | Proceso mejorado de preparación de nanopartículas lipídicas cargadas de arnm. | |
| BR112016030852A2 (pt) | encapsulação de rna mensageiro | |
| EA202191313A1 (ru) | Композиции на основе липидных наночастиц | |
| MX2019005470A (es) | Formulación de nanopartículas lipídicas basadas en ice mejorada para el suministro de arnm. | |
| PH12023500013A1 (en) | Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof | |
| CY1123984T1 (el) | Συνθεσεις και μεθοδοι για λυοφιλες μορφες νανοσωματιδιων | |
| AR113031A1 (es) | Composiciones de nanopartículas lipídicas (lnp) que comprende arn | |
| BR112022001192A2 (pt) | Composições estáveis de nanopartículas lipídicas carregadas com mrna e processos de produção | |
| CY1125308T1 (el) | Συνθεσεις και μεθοδοι για τη χορηγηση θεραπευτικων παραγοντων | |
| MX2024000327A (es) | Composiciones y metodos para la administracion de arn mensajero. | |
| MX2024015149A (es) | Lipidos cationicos ionizables y nanoparticulas lipidicas, y metodos de sintesis y uso de los mismos | |
| CY1121348T1 (el) | Mrna θεραπεια για την θεραπευτικη αγωγη οφθαλμικων ασθενειων | |
| BR112022019124A2 (pt) | Composições e métodos para liberação de rna | |
| MX2024009361A (es) | Lipidos cationicos ionizables para nanoparticulas lipidicas | |
| BR112015005940A2 (pt) | processo para a preparação de nanopartículas terapêuticas | |
| EA201890864A1 (ru) | Композиции и способы для ингибирования генной экспрессии лпа | |
| BR112018003110A2 (pt) | nanopartículas terapêuticas compreendendo um agente terapêutico e métodos de fabricação e uso dos mesmos | |
| MX2018006989A (es) | Metodos y composiciones para el tratamiento contra un trastorno asociado a serpinc1. | |
| EP4649950A3 (en) | Complement component c5 irna compositions and methods of use thereof | |
| WO2018183808A9 (en) | Antiviral therapeutic | |
| WO2016201301A8 (en) | Complement component c5 irna compositions and methods of use thereof | |
| MX376247B (es) | Formulacion que comprende particulas. | |
| WO2017214518A8 (en) | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) | |
| MX2014014590A (es) | Microcapsulas que contienen retinoides, su procedimiento de preparacion y composiciones farmaceuticas que los contienen. | |
| BR112015023173A2 (pt) | método e aparelho para fornecer e operar um cartão de exibição de pagamento aprimorado com um suporte de rede |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |